Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012)

NCT ID: NCT01629927

Last Updated: 2012-06-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study proposes to enroll male subjects affected by Hypohidrotic Ectodermal Dysplasia (XLHED). The sweat duct images will be acquired with a CE marked skin-imaging device and the sweat rate will be measured using a CE marked pilocarpine iontophoresis and collection system. The technologies for both imaging of sweat ducts and the measurement of maximal sweat rate have been used safely and without adverse events in our prior studies involving HED/XLHED subjects. Furthermore, this study will assess the feasibility of developing a non-invasive screening tool that will enable detection of clinical signs of XLHED based on an analysis of a two dimensional frontal photograph.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study proposes to enroll male subjects affected by XLHED (determined by genetic testing and restricted to age \> 1 yr). The sweat duct images will be acquired with a CE marked skin-imaging device and the sweat rate will be measured using a CE marked pilocarpine iontophoresis and collection system. The technologies for both imaging of sweat ducts and the measurement of maximal sweat rate have been used safely and without adverse events in our prior studies involving HED/XLHED subjects. Furthermore, this study will assess the feasibility of developing a non-invasive screening tool that will enable detection of clinical signs of XLHED based on an analysis of a two dimensional frontal photograph.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

X-linked Hypohidrotic Ectodermal Dysplasia Hypohidrotic Ectodermal Dysplasia

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HED-affected males

Male subjects affected by HED

No interventions assigned to this group

Male controls

Male subjects not affected by HED

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects must meet all of the following criteria to be enrolled in this study.

* Attending the 2012 Spanish Association for those Affected by Ectodermal Dysplasia Annual Reunion;
* One year of age or greater;
* Conform to one of the following requirements for providing informed consent/assent:

* If more than 18 years of age, subjects must provide signed informed consent;
* If less than 18 years of age and it is determined that the subject is capable of providing assent, both the assent of the subject and consent of the parent(s) or guardian of that subject must be granted. Under this condition, both parents of the subject should give their permission, unless 1 parent is deceased, unknown, incompetent, or not available;
* If the subject is incapable of providing assent, the consent of the parent(s) or guardian of the subject must be granted. Under this condition, both parents should give their consent, unless 1 parent is deceased, unknown, incompetent, or not available.
* Can provide documentation of genetic testing results positive for an EDA gene mutation /deletion;
* As described in Section 3.2 above, subjects must meet one of the following criteria:

* Documented diagnosis of XLHED confirmed via genetic testing;
* Unaffected male controls.

Exclusion Criteria

* Known hypersensitivity to pilocarpine or pilocarpine-like muscarinic agonists;
* Presence of pacemakers;
* Subjects who are not able or are not willing to comply with the procedures of this protocol;
* Subjects with any major medical problem that will prevent them from participating in this study.
Minimum Eligible Age

1 Year

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edimer Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Encarna Navarro, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Virgen de la Arrixaca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for Rare Diseases

Burgos, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ECP-012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MCT8 Deficiency Caregiver Study
NCT06060197 COMPLETED
Study of Skeletal Disorders
NCT05031507 RECRUITING
Primordial Dwarfism Registry
NCT04569149 RECRUITING